Eli Lilly (LLY) agreed to acquire AtaiBeckley (ATAI) in an all-cash deal valued up to $3.8B, expanding its neuroscience pipeline. The definitive announcement signals a meaningful growth investment for Lilly and should be supportive for biotech deal sentiment.
Eli Lilly (LLY) agreed to acquire AtaiBeckley (ATAI) in an all-cash deal valued up to $3.8B, expanding its neuroscience pipeline. The definitive announcement signals a meaningful growth investment for Lilly and should be supportive for biotech deal sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
